Evaluate Bone Changes in Patients With PsA

Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months

Abatacept 125 MG/ML

University Clinic Erlangen, Medical Department 3, Rheumatology & Immunology

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB

Change in bone erosion volume measured by Hr-PQ CT of the involved hand between baseline and 24 weeks follow-up

Change in bone erosion on CT between baseline and 24 wks

Change in osteophytes CT between baseline and 24 wks

Change in MRI Tenosynovitis score between baseline compared to month 3 and 6

Change in PSAMRIS MRI score between baseline compared to month 3 and 6

Change in MRI bone erosions between baseline compared to month 3 and month 6

Change in MRI synovitis between baseline compared to month 3 and month 6

Change of DAS28 between baseline compared to month 3 and month 6

Change of DAPSA between baseline compared to month 3 and month 6

Change of MDA between baseline compared to month 3 and month 6

Change of HAQ-DI between baseline compared to month 3 and month 6

Change of SPARCC between baseline compared to month 3 and month 6

Change of PSAID between baseline compared to month 3 and month 6

Change of PASI between baseline compared to month 3 and month 6

Change of SF36 between screening, month 3 and month 6

University of Erlangen-Nürnberg Medical School

The study is a single arm interventional study with a treatment phase of 6 months.

Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :
dynamometry exam
walking test
Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia & Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire.

Spondylarthropathy

Sarcopenia

Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength

Dynamometry exam

A 4 metres walking test will be performed to assess patient's walking speed

Walking test

DXA measurement will be performed to assess patient's body composition

DXA measurement

Patient's quality of life will be assessed thanks to the SARQOL questionnaire

SARQOL questionnaire

Life habits Questionnaire

Service de Rhumatologie - Hôpital Edouard Herriot

Sarcopenia in Axial and Peripheral Spondyloarthropathies

Muscular strength is the first outcome to evaluate sarcopenia

Walking speed is a physical performance outcome, that is the second outcome to evaluate sarcopenia

Muscular mass is the third outcome to evaluate sarcopenia and will be assessed using DXA

Number of hours of sport practice per month is the first outcome to evaluate patient's global physical activity.

Physical activity rate in work can be light, medium, high or not applicable if the patient does not work ; it is the second outcome to evaluate patient's physical global activity.

Average walking time in a week is the third outcome to evaluate patient's physical global activity.

Quality of life will be assessed thanks to the SARQOL questionnaire (score between 0 and 100)

Hospices Civils de Lyon

Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection

Hyperostosis, Diffuse Idiopathic Skeletal

Metabolic Syndrome

Diabetes Mellitus

PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints

Thoracic spine x-rays+whole spine MRI

blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.

blood tests

demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference

constitutional and demographic data collection

HaEmek MC and Chaim Sheba MC

Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)

inflammatory bone marrow edema lesions and fatty lesions and the anterior and posterior corners of the spine (Berlin score) as well as for the presence of enthesitis on the posterior elements.
The sacroiliac joints will also be scored according to the Berlin scoring method for the presence of acute and structural inflammatory lesion, including BME, fat metaplasia, erosions, sclerosis, ankylosis. Anterior and posterior extraarticular enthesitis will also be registered

Other researchers are expected to perform the study in their own countries. If they perform the study, unidentified data from the present study will be processed with the other parties data.

spondylarthropathies/adipositas

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Sarcopenia in Axial and Peripheral Spondyloarthropathies

Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird